Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma
- 267 Downloads
Hyaluronic acid (HA) has been proposed as a biochemical marker of malignant pleural mesothelioma (MPM). The present study focused on the implications of HA and CD44 interaction in the proliferation and invasiveness of MPM. The proliferation and invasive activity was evaluated in two human mesothelioma cell lines, ACC-MESO-1 and K921MSO, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and the transwell chamber model. The knockdown of CD44 gene expression was accomplished by transfection of the cells with small interfering RNA. Flow cytometry revealed that both the ACC-MESO-1 and K921MSO cell lines highly expressed CD44. Treatment with HA enhanced the proliferation in both mesothelioma cell lines in comparison to cells without HA treatment. The treatment with HA (25 μg/ml) also significantly upregulated the invasion of both types of cells. The silencing of CD44 significantly abrogated the effect of HA treatment on the proliferation of ACC-MESO-1 cells and significantly suppressed the proliferation of K921MSO cells. HA–CD44 binding is important for the migration and proliferation of mesothelioma cells. Therefore, the HA–CD44 interaction is a potentially useful therapeutic target in MPM.
KeywordsMalignant pleural mesothelioma Hyaluronic acid CD44 Proliferation
This study was supported in part by a UOEH Research Grant for the Promotion of Occupational Health and a Grant-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan. We thank Yukari Furutani, Misako Fukumoto, and Yukiko Koyanagi for their expert technical help.
Conflicts of interest
- 8.Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–12.PubMedCrossRefGoogle Scholar
- 9.Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.PubMedCrossRefGoogle Scholar
- 23.Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. Hyaluronan–CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase Cε–Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006;281:14026–40.PubMedCrossRefGoogle Scholar
- 29.Li CZ, Liu B, Wen ZQ, Li HY. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol. 2008;54:180–6.Google Scholar